Q-omics provides the consensus-scored RRBP1 profile across patient tissues and cancer cell-line models. RRBP1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RRBP1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, RRBP1 protein abundance shows 26,812 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, HNSC, and LSCC as cancer lineages where RRBP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RRBP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RRBP1 survival associations across molecular data types. RRBP1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RRBP1 RNA expression–survival associations across cancer types. High RRBP1 expression shows unfavorable associations in MESO, BLCA, LGG, CESC and SARC, but favorable associations in ACC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify MESO as the clearest survival context for RRBP1 RNA expression.
This table summarizes RRBP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RRBP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RRBP1 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, STAD, KIRP and BRCA. The HNSC box plot shows higher RRBP1 RNA expression in tumor versus normal tissue (log2 FC = +0.817, t-test p < 0.001).
This table shows molecular features associated with RRBP1 in patient tissues and cancer cell lines. In patient samples, RRBP1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RRBP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BONE.
